How is the mutational status for tumor suppressors p53 and p16INK4A in MFH of the bone?

被引:8
|
作者
Taubert, H
Berger, D
Hinze, R
Meye, A
Würl, P
Hogendoorn, PCW
Holzhausen, HJ
Schmidt, H
Rath, FW
机构
[1] Univ Halle Wittenberg, Inst Pathol, D-06097 Halle, Germany
[2] Univ Halle Wittenberg, Ctr Basic Med Res, D-06097 Halle, Germany
[3] Univ Halle Wittenberg, Clin Gen Surg, D-06097 Halle, Germany
[4] Acad Hosp Leiden, Dept Pathol, NL-2300 RC Leiden, Netherlands
关键词
malignant fibrous histiocytoma of the bone; p53; p16; tumor suppressor genes; mutational analysis;
D O I
10.1016/S0304-3835(97)00423-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Both tumor suppressor genes p53 and p16(INK4A) play a crucial role in the control of cell cycle and tumor development. In this study 19 malignant fibrous histiocytomas of the bone (MFH-b), a very rare sarcoma entity, were investigated for mutations in p53 and p16 genes by a PCR-SSCP-sequencing analysis. In the tumor samples two p53 mutations and two polymorphisms (one in the p53 gene and one in the p16 gene) were found. The occurrence rate for p53 mutations and the absence of p16 mutations in MFH-b are comparable to the findings for MFH of soft tissues (MFH-st) and osteosarcomas, suggesting that p53 rather than p16 may play a role in tumorigenesis of MFH-b. (C) 1998 Elsevier Science Ireland Ltd.
引用
收藏
页码:147 / 151
页数:5
相关论文
共 50 条
  • [1] Protein expression of the tumor suppressors p16INK4A and p53 and disease progression in recurrent respiratory papillomatosis
    Pham, True T.
    Ongkeko, Weg M.
    An, Yi
    Yi, Eunhee S.
    LARYNGOSCOPE, 2007, 117 (02): : 253 - 257
  • [2] p16INK4a and p53 deficiency cooperate in tumorigenesis
    Sharpless, NE
    Alson, S
    Chan, S
    Silver, DP
    Castrillon, DH
    DePinho, RA
    CANCER RESEARCH, 2002, 62 (10) : 2761 - 2765
  • [3] Hypermethylation-associated inactivation of p14ARF is independent of p16INK4a methylation and p53 mutational status
    Esteller, M
    Tortola, S
    Toyota, M
    Capella, G
    Peinado, MA
    Baylin, SB
    Herman, JG
    CANCER RESEARCH, 2000, 60 (01) : 129 - 133
  • [4] pRB, p53, p16INK4a senescence and malignant transformation
    Larsen, CJ
    BULLETIN DU CANCER, 2004, 91 (05) : 399 - 402
  • [5] Absence of p16INK4a and truncation of ARF tumor suppressors in chickens
    Kim, SH
    Mitchell, M
    Fujii, H
    Llanos, S
    Peters, G
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (01) : 211 - 216
  • [6] The battle between tumor suppressors:: Is gene therapy using p16INK4a more efficacious than p53 for treatment of ovarian carcinoma?
    Murphy, ME
    CLINICAL CANCER RESEARCH, 2001, 7 (06) : 1487 - 1489
  • [7] p16INK4a is a prognostic marker in resected ductal pancreatic cancer -: An analysis of p16INK4a, p53, MDM2, an Rb
    Gerdes, B
    Ramaswamy, A
    Ziegler, A
    Lang, SA
    Kersting, M
    Baumann, R
    Wild, A
    Moll, R
    Rothmund, M
    Bartsch, DK
    ANNALS OF SURGERY, 2002, 235 (01) : 51 - 59
  • [8] Clinical Significance of p53 and p16ink4a Status in a Contemporary North American Penile Carcinoma Cohort
    Zargar-Shoshtari, Kamran
    Spiess, Philippe E.
    Berglund, Anders E.
    Sharma, Pranav
    Powsang, Julio M.
    Giuliano, Anna
    Magliocco, Anthony M.
    Dhillon, Jasreman
    CLINICAL GENITOURINARY CANCER, 2016, 14 (04) : 346 - 351
  • [9] p16INK4a modulates p53 in primary human mammary epithelial cells
    Zhang, Jianmin
    Pickering, Curtis R.
    Holst, Charles R.
    Gauthier, Mona L.
    Tlsty, Thea D.
    CANCER RESEARCH, 2006, 66 (21) : 10325 - 10331
  • [10] Alterations in the p16INK4a and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts
    Noble, JR
    Zhong, ZH
    Neumann, AA
    Melki, JR
    Clark, SJ
    Reddel, RR
    ONCOGENE, 2004, 23 (17) : 3116 - 3121